Tinostamustine - Mundipharma EDO

Drug Profile

Tinostamustine - Mundipharma EDO

Alternative Names: Bendamustine-vorinostat fusion molecule; EDO S101; NL-101

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Northlake International
  • Developer Mundipharma EDO
  • Class Antineoplastics; Benzimidazoles; Small molecules
  • Mechanism of Action Alkylating agents; Antimetabolites; Apoptosis stimulants; DNA cross linking agents; DNA synthesis inhibitors; Histone deacetylase inhibitors; Mitosis modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Haematological malignancies

Most Recent Events

  • 26 Oct 2017 Chemical structure information added
  • 10 Oct 2017 Phase-I/II clinical trials in Solid tumours (Second-line therapy or greater) in USA (IV)
  • 01 Mar 2016 Phase-I clinical trials in Haematological malignancies (Second-line therapy or greater) in Italy and Switzerland (IV) after March 2016 (NCT02576496)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top